ArticleBMC biology2025
KLF13 promotes ferroptosis and chemosensitivity in lung adenocarcinoma.
Article in BMC biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Identification and validation of prognostic genes associated with integrative stress response in lung adenocarcinoma and construction of the risk models.Scientific reports · 2026Article
- Exosomal miR-3126-5p derived from cancer-associated fibroblasts facilitates glycolysis to accelerate NSCLC progression by targeting KLF13 to activate the SH2B1/IRS1 axis.Clinical and translational medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundFerroptosis, a form of cell death reliant on iron metabolism dysregulation and lipid peroxidation, has emerged as a promising target for improving tumor drug resistance. This study aims to unveil the underlying molecular mechanisms of Kruppel-like factor 13 (KLF13) in ferroptosis and chemotherapy sensitivity in lung adenocarcinoma (LUAD).
resultsWe conducted RNA sequencing on lung adenocarcinoma cells treated with ferroptosis inducers and found that the expression level of KLF13 changed during ferroptosis, suggesting its potential involvement in this process. Subsequently, we generated stable cell lines overexpressing and knocking down KLF13. Cytotoxicity assays and reactive oxygen species (ROS) detection demonstrated that overexpression of KLF13 promoted ferroptosis induced by IKE and RSL3 in LUAD cells, whereas silencing KLF13 inhibited ferroptosis. Furthermore, overexpression of KLF13 enhanced the chemotherapeutic efficacy of cisplatin and pemetrexed. RNA-seq, qPCR, and western blot experiments revealed that KLF13 downregulated the RNA and protein expression of GPX4. ChIP assays and dual-luciferase reporter gene assays indicated that KLF13 directly bound to the promoter region of GPX4, inhibiting transcriptional activity of GPX4. Additionally, overexpression and knockdown of GPX4 could reverse the effects of KLF13 on ferroptosis and chemosensitivity. These findings were further confirmed through immunohistochemical staining and animal experiments.
conclusionsOur study reveals that KLF13 promotes ferroptosis in LUAD by inhibiting GPX4, thereby enhancing sensitivity to chemotherapy drugs. Overall, targeting KLF13 may contribute to developing new therapeutic strategies for LUAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.